CeriBell, Inc (CBLL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CeriBell, Inc stock (CBLL) is currently trading at $18.92. CeriBell, Inc PS ratio (Price-to-Sales) is 7.82. Analyst consensus price target for CBLL is $27.86. WallStSmart rates CBLL as Sell.
- CBLL PE ratio analysis and historical PE chart
- CBLL PS ratio (Price-to-Sales) history and trend
- CBLL intrinsic value — DCF, Graham Number, EPV models
- CBLL stock price prediction 2025 2026 2027 2028 2029 2030
- CBLL fair value vs current price
- CBLL insider transactions and insider buying
- Is CBLL undervalued or overvalued?
- CeriBell, Inc financial analysis — revenue, earnings, cash flow
- CBLL Piotroski F-Score and Altman Z-Score
- CBLL analyst price target and Smart Rating
CeriBell, Inc
📊 No data available
Try selecting a different time range
Smart Analysis
CeriBell, Inc (CBLL) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
CeriBell, Inc (CBLL) Key Strengths (2)
Revenue surging 33.70% year-over-year
85.28% of shares held by major funds and institutions
Supporting Valuation Data
CeriBell, Inc (CBLL) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium valuation at 7.8x annual revenue
Premium pricing at 4.5x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
CeriBell, Inc (CBLL) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 33.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (7.82), Price/Book (4.49) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -30.80%, Operating Margin at -58.90%, Profit Margin at -60.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -30.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 33.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CBLL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CBLL's Price-to-Sales ratio of 7.82x trades 26% below its historical average of 10.6x (29th percentile). The current valuation is 67% below its historical high of 23.61x set in Nov 2024, and 21% above its historical low of 6.44x in Sep 2025. Over the past 12 months, the PS ratio has compressed from ~11.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for CeriBell, Inc (CBLL) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
CeriBell, Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 89M with 34% growth year-over-year. The company is currently unprofitable, posting a -60.0% profit margin.
Key Findings
Revenue growing at 34% YoY, reaching 89M. This pace significantly outperforms most MEDICAL DEVICES peers.
The company is unprofitable with a -60.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can CeriBell, Inc maintain 34%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact CeriBell, Inc.
Bottom Line
CeriBell, Inc is a high-conviction growth story with revenue accelerating at 34% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -60.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:06:55 AM
About CeriBell, Inc(CBLL)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.